# Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

> **NCT06177522** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jinling Hospital, China** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Cancer
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** albumin-bound paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT06177522
- **Lead sponsor:** Jinling Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-30
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06177522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06177522, "Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06177522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*